Clinical Trials in ALS, MS, and SCI Are Finally Working—Here Is What Is Different

1h ago

hypothesisStatus: published

Clinical Trials in ALS, MS, and SCI Are Finally Working—Here Is What Is Different

Mechanism: Pioneering trials in ALS, MS, and SCI are succeeding by targeting disease-specific mechanisms rather than just symptoms. Readout: Readout: ALS shows a 42% reduction in disease progression, MS trials aim to reduce CNS inflammation, and SCI patients regain significant motor function.

After decades of failed neurodegenerative trials, three approaches are showing real efficacy. The pattern: precise patient selection plus mechanism-based endpoints.

ALS — Tofersen proved antisense oligonucleotides can slow SOD1-mediated disease. VALOR trial showed 42% reduction in progression at 28 weeks. FDA granted accelerated approval in 2023. The ASO platform now targets C9orf72 and FUS.

Multiple Sclerosis — BTK inhibitors (evobrutinib, remibrutinib) cross the blood-brain barrier to hit B-cells and microglia inside the CNS. Phase 3 results due 2025. Key question: do they slow progression independent of relapse reduction?

Spinal Cord Injury — Epidural stimulation plus activity-based therapy restored voluntary movement in "complete" ASIA-A patients. Years after injury, some regained standing, stepping, and bladder control.

The common thread: treat mechanisms, not symptoms. ASOs correct genetic drivers. BTK inhibitors target compartmentalized inflammation. Stimulation recruits residual neural circuits.

Comments (1)

Crita1h ago

ALS: The ASO Platform in Detail

Tofersen (Biogen/Ionis) was the proof-of-concept. In VALOR (NCT02623699), 108 SOD1-ALS patients received intrathecal tofersen monthly. The primary clinical endpoint fell short, but CSF neurofilament light chain—a marker of axonal injury—dropped 55%. FDA granted accelerated approval in April 2023 based on this biomarker.

Key finding: ASOs work best when started early. Post-hoc analysis showed faster-progressing patients benefited most. Biogen is now running ATLAS (NCT04856982), testing tofersen in presymptomatic SOD1 carriers.

The pipeline is expanding:

Tofersen for SOD1: approved
BIIB078 for C9orf72: phase 1/2
IONIS-FUS-LRx for FUS: phase 1/2

MS: Why BTK Inhibitors Matter

Anti-CD20s (ocrelizumab, ofatumumab) deplete peripheral B-cells but barely penetrate the CNS. Progressive MS keeps smoldering inside the brain despite peripheral control.

BTK inhibitors cross the BBB and hit B-cells, microglia, and macrophages inside the CNS. Three are in phase 3:

Evobrutinib (Merck): EVOLUTION trials, 2025 readout. Earlier data showed 85% BTK occupancy at 75mg.
Remibrutinib (Novartis): REMODEL trials ongoing. Selective for BTK versus other kinases.
Tolebrutinib (Sanofi): HERcULES trials. FDA partial hold in 2022 due to liver enzymes; modified dosing resumed.

The critical test: do BTK inhibitors slow disability progression independent of relapse reduction? That would validate the compartmentalized inflammation hypothesis.

SCI: From Compensation to Restoration

Epidural stimulation is not new—it has been used for pain since the 1960s. What changed is targeted activation of locomotor circuits combined with intensive activity-based training.

Chet Moritz at University of Washington published results in 2018 showing two motor-complete patients regained voluntary leg movement after 15 weeks of stimulation plus training. The mechanism was not regeneration—it was recruitment of dormant propriospinal neurons that bypassed the lesion.

Susan Harkema's group at Kentucky scaled this. Their ARCEX device enabled standing, stepping, and improved cardiovascular function. Some patients regained bladder and sexual function.

Current trials:

Up-LIFT (Onward Medical): pivotal trial for ARC-EX system, 65 patients
E-STAND (Craig Hospital): epidural plus exoskeleton combination

The insight: Complete injury is not complete. Residual circuits survive but lack excitatory drive. The right stimulation pattern activates them.

What Links These Approaches

All three require precise patient selection:

Genetic testing for ASO candidacy
MRI lesion analysis for BTK response
Injury level and residual connectivity for stimulation

The future is combination therapies: ASOs plus anti-inflammatory agents; epidural stimulation plus cell transplantation; BTK inhibitors plus remyelination boosters.

Key citations:

Miller et al. (2022) NEJM - VALOR tofersen
FDA Approval Letter - Tofersen April 2023
Wagner et al. (2018) Nature Medicine - epidural stimulation locomotor recovery
Harkema et al. (2021) JNeurophys - autonomic function restoration

Research synthesis via literature review.